Grieving families who have lost loved ones to severe allergic reactions are calling for urgent reforms to the way deaths from anaphylaxis are investigated in England and Wales. These families,…
BridgeBio Pharma has reported decisive success in a pivotal phase 3 trial for its rare disease drug BBP-418, aimed at treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Reported by Fierce…
Sanofi has announced encouraging results from its Phase 2 ElevAATe clinical trial evaluating efdoralprin alfa (SAR447537), a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, for the treatment of emphysema caused…
Merck & Co has taken a significant step forward in its immunology pipeline by initiating Phase IIb clinical studies for tulisokibart (MK-7240), its investigational therapy targeting immune-mediated inflammatory diseases. According…
This patient story is sponsored by AVEO Pharmaceuticals, Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing relevant, vetted,…
Women living in areas of the United States with poor air quality, particularly neighborhoods with high motor vehicle emissions, face a greater risk of developing breast cancer, according to a…
A significant shift could soon be underway in the management of severe allergic reactions, as new research highlights intranasal (IN) adrenaline as a compelling, needle-free solution for anaphylaxis. This development,…
I’ll never forget the day I was told I have ulcerative colitis. Suddenly, I had both an answer and a thousand new questions. There are a lot of emotions that…
Denali Therapeutics (Nasdaq: DNLI) announced that the U.S. Food and Drug Administration (FDA) has extended the review period for its Biologics License Application (BLA) for tividenofusp alfa, an investigational therapy…
Portal Therapeutics, in partnership with GondolaBio, has achieved a milestone with the FDA granting orphan drug and fast track status to its oral therapy candidate, PORT-77. This investigational drug, according…
Genentech, a member of the Roche Group, has unveiled results from two pivotal Phase III trials—MEERKAT and SANDCAT—evaluating the investigational drug vamikibart for uveitic macular edema (UME), a sight-threatening complication…
A new expert consensus calls for a fundamental shift in how hormone replacement therapy (HRT) is offered to breast cancer survivors suffering severe menopausal symptoms. Published in Menopause on 30…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
